NCT06198907View on ClinicalTrials.gov

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Golidocitinib

Daily dosing of golidocitinib

DRUG

Sintilimab

Sintilimab, 200mg, intravenous, every 3 weeks.

DRUG

platinum doublet chemotherapy

Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Collaborators (1)

Dizal Pharmaceuticals
All Listed Sponsors
collaborator

Dizal Pharmaceuticals

INDUSTRY

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER